Advertisement
Australia markets closed

  • ALL ORDS

    7,895.90
    -39.80 (-0.50%)
     

  • AUD/USD

    0.6609
    -0.0006 (-0.09%)
     

  • ASX 200

    7,628.20
    -37.40 (-0.49%)
     

  • OIL

    78.92
    -0.31 (-0.39%)
     

  • GOLD

    2,355.30
    -8.80 (-0.37%)
     

  • Bitcoin AUD

    102,286.20
    -499.12 (-0.49%)
     

  • CMC Crypto 200

    1,455.73
    -0.14 (-0.01%)
     

Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Equity Research
·2-min read

For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76, compared to $3.05 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $2.56 billion, representing a surprise of +5.15%. The company delivered an EPS surprise of +16.10%, with the consensus EPS estimate being $4.10.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Vertex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Geographic Revenues- United States: $1.52 billion versus $1.56 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change.

  • Geographic Revenues- Outside of the United States: $1.17 billion compared to the $997.71 million average estimate based on three analysts.

  • Revenues by Product- Trikafta/Kaftrio: $2.48 billion compared to the $2.41 billion average estimate based on eight analysts. The reported number represents a change of +18.5% year over year.

View all Key Company Metrics for Vertex here>>>

Shares of Vertex have returned +1.4% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research